MAP2K4

Across TCGA pan-cancer cohorts, MAP2K4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP2K4 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP2K4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAP2K4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where MAP2K4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.978	0.625	.003	48	view →
HNSC	DFS	Quartile	II,III,IV	0.909	0.737	.023	12	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	9	view →
GBM	OS	Quartile	All	0.326	0.705	.017	4	view →
LUAD	OS	Median	All	0.906	0.625	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP2K4–CCRCC (OS)

Open the CCRCC breakdown →